Fairmount Funds Management LLC bought $18M of CBIO
director, owner at GLYCOMIMETICS INC. 1,360,000 shares at an average of $13.41, traded Dec 4, 2025, filed Dec 8, 2025.
Score components
- +15RoleDirector
- +25Trade size$18.2M at market
- +10Relative to holdingsHoldings up 98%
- +8Price context64% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -16.9%, 3m -8.7%, 6m +31.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-119320, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 4, 2025 | POpen-market purchase Ordinary Sharesindirect: By Fairmount Healthcare Fund II L.P. | +1,360,000 | $13.41 | $18M | 2,747,866 | Dec 8, 2025 |
| Dec 4, 2025 | POpen-market purchase Pre-Funded Warrant (Right to Buy)derivativeindirect: By Fairmount Healthcare Fund II L.P. | +131,434 | $13.41 | $1.8M | 1,768,140 | Dec 8, 2025 |
Related signals
Other insiders at GLYCOMIMETICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | GLYCOMIMETICS INC | Barbara Harlin Bispham See Remarks | $11k 620 shares | -3% | |
| 31Weak | GLYCOMIMETICS INC | Joshua T Brumm Chief Executive Officer | $160k 9,447 shares | -3% | |
| 23Weak | GLYCOMIMETICS INC | Jonathan McNeill President and COO | $77k 4,570 shares | -3% | |
| 17Weak | GLYCOMIMETICS INC | Richard William Scalzo Chief Financial Officer | $10k 568 shares | -3% | |
| 10Weak | GLYCOMIMETICS INC | Ellie Eunkyung Im Chief Medical Officer | $11k 623 shares | -3% | |
| 10Weak | GLYCOMIMETICS INC | Jan Pinkas Chief Scientific Officer | $12k 658 shares | -3% | |
| 10Weak | GLYCOMIMETICS INC | Ryan Lynch See Remarks | $4,296 240 shares | -2% | |
| 54Moderate | CBIObuy GLYCOMIMETICS INC | Fairmount Funds Management LLC director, owner | $12M 853,450 shares | +31% | |
| 10Weak | GLYCOMIMETICS INC | Barbara Harlin Bispham See Remarks | $22k 1,218 shares | -6% | |
| 47Moderate | GLYCOMIMETICS INC | Joshua T Brumm Chief Executive Officer | $761k 42,305 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.